Why the study?
The optimal frequency for cardiac monitoring of LVEF in patients receiving trastuzumab-based therapy for early breast cancer is unknown.
Does cardiac monitoring every 4 months provide non-inferior detection of LVEF changes compared to every 3 months in patients receiving trastuzumab for early breast cancer?
Does cardiac monitoring every 4 months provide non-inferior detection of LVEF changes compared to every 3 months in patients receiving trastuzumab for early breast cancer?
Cardiac monitoring every 4 months is non-inferior to every 3 months for detecting LVEF changes in patients receiving trastuzumab for early breast cancer, supporting a less frequent and more convenient monitoring strategy.
Answers are grounded in this paper and cite their sources.
4-monthly LVEF monitoring may be adopted in trastuzumab-treated EBC; extends RCT evidence supporting de-intensified cardiac surveillance.
PURPOSE: The optimal frequency for cardiac monitoring of left ventricular ejection fraction (LVEF) in patients receiving trastuzumab-based therapy for early breast cancer (EBC) is unknown. We conducted a randomized controlled trial comparing 3- versus 4-monthly cardiac monitoring. PATIENTS AND METHOD: Patients scheduled to receive trastuzumab-containing cancer therapy for EBC with normal (>53%) baseline LVEF were randomized to undergo LVEF assessments every 3 or 4 months. The primary outcome was the change in LVEF from baseline. Secondary outcomes included the rate of cardiac dysfunction (defined as a decrease in the LVEF of ≥10 percentage points, to a value <53%), delays in or discontinuation of trastuzumab therapy, and cardiology referral. RESULTS: Of the 200 eligible and enrolled patients, 100 (50%) were randomized to 3-monthly and 100 (50%) to 4-monthly cardiac monitoring. Of these patients, 98 and 97 respectively underwent at least one cardiac scan. The estimated mean difference in LVEF from baseline was -0.94% (one-sided 95% lower bound: -2.14), which exceeded the pre-defined non-inferiority margin of -4%. There were also no significant differences between the two study arms for any of the secondary endpoints. The rate of detection of cardiac dysfunction was 16.3% (16/98) and 12.4% (12/97) in the 3- and 4-monthly arms, respectively (95% CI: 4.0 [-5.9, 13.8]). CONCLUSIONS: Cardiac monitoring every 4 months was deemed non-inferior to that every 3 months in patients with HER2-positive EBC being treated with trastuzumab-based therapy. Given its costs and inconvenience, cardiac monitoring every 4 months should be considered standard practice. Registration: NCT02696707, 18 February 2016.
No takes yet. Share an insight, caveat, or question.
Dent et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: